Home › Funds › ORBIMED ADVISORS LLC › SPRY
ORBIMED ADVISORS LLC position in SPRY
ARS PHARMACEUTICALS INC · Health Care
ORBIMED ADVISORS LLC reported holding 8,288,510 shares of SPRY (ARS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$66.4M, representing 1.33% of its reported portfolio and ranking #20 among its reported holdings. ORBIMED ADVISORS LLC has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ORBIMED ADVISORS LLC's SPRY position evolved
ORBIMED ADVISORS LLC first disclosed a stake in SPRY in Q3 2023 at 9,240,887 shares (US$34.9M). The position peaked in Q2 2025 at 8,288,510 shares, worth US$144.6M. Across 12 filings, ORBIMED ADVISORS LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 8,288,510 shares valued at US$66.4M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 9.24M | $34.93M | New |
| Q4 2023 | 9.24M | $50.64M | Hold |
| Q1 2024 | 9.24M | $94.44M | Hold |
| Q2 2024 | 9.24M | $78.64M | Hold |
| Q3 2024 | 8.29M | $120.18M | Reduce |
| Q4 2024 | 8.29M | $87.44M | Hold |
| Q1 2025 | 8.29M | $104.27M | Hold |
| Q2 2025 | 8.29M | $144.63M | Hold |
| Q3 2025 | 8.29M | $83.30M | Hold |
| Q4 2025 | 8.29M | $96.56M | Hold |
| Q1 2026 | 8.29M | $66.56M | Hold |
| Q2 2026 | 8.29M | $66.39M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SPRY and 13F data
SPRY (ARS PHARMACEUTICALS INC) is a Health Care company. 24 other funds we track also report a position in SPRY — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$87.0M), Rubric Capital Management LP (US$68.4M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$60.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SPRY
- RA CAPITAL MANAGEMENT, L.P. 10.86M sh · $87.00M · Q2 2026
- Rubric Capital Management LP 8.54M sh · $68.41M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 7.50M sh · $60.11M · Q2 2026
- Tyro Capital Management LLC 4.46M sh · $35.72M · Q2 2026
- SR ONE CAPITAL MANAGEMENT, LP 4.01M sh · $32.14M · Q2 2026
- GENERAL AMERICAN INVESTORS CO INC 1.13M sh · $9.08M · Q2 2026
- Third Point 1.00M sh · $8.01M · Q2 2026
- Third Point LLC 1.00M sh · $8.01M · Q2 2026
- Tejara Capital Ltd 607.04K sh · $4.86M · Q2 2026
More on ORBIMED ADVISORS LLC
FAQ
How long has ORBIMED ADVISORS LLC held SPRY?
ORBIMED ADVISORS LLC has disclosed SPRY holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is ORBIMED ADVISORS LLC's current position in SPRY?
As of Q2 2026, ORBIMED ADVISORS LLC holds 8.29M shares of SPRY (ARS PHARMACEUTICALS INC), valued at $66.39M, representing 1.33% of its reported portfolio and ranking #20.
Has ORBIMED ADVISORS LLC been buying or selling SPRY?
In the latest 13F filing (Q2 2026), ORBIMED ADVISORS LLC held unchanged its position in SPRY. The position peaked in Q2 2025 at 8.29M shares.
Which other funds hold SPRY?
Other major institutional holders of SPRY include RA CAPITAL MANAGEMENT, L.P., Rubric Capital Management LP, DEERFIELD MANAGEMENT COMPANY, L.P., among 24 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.